Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

ClinicalTrials.gov ID: NCT02141672

Public ClinicalTrials.gov record NCT02141672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis

Study identification

NCT ID
NCT02141672
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Enrollment
265 participants

Conditions and interventions

Interventions

  • Voclosporin High Dose Drug
  • Voclosporin Low Dose Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2014
Primary completion
Jun 30, 2016
Completion
Dec 31, 2016
Last update posted
May 17, 2021

2014 – 2017

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
14
Facility City State ZIP Site status
AURA-LV Site Los Angeles California 90095
AURA-LV Site Palo Alto California 94305
AURA-LV Site Gainesville Florida 32610
AURA-LV Site Miami Florida 33165
AURA-LV Site Farmington Hills Michigan 48334
AURA-LV Site Brooklyn New York 11203
AURA-LV Site New York New York 10016
AURA-LV Site Chapel Hill North Carolina 27599
AURA-LV Site Charlotte North Carolina 28204
AURA-LV Site Columbus Ohio 43210
AURA-LV Site Hershey Pennsylvania 17033
AURA-LV Site Chattanooga Tennessee 37408
AURA-LV Site Dallas Texas 75390
AURA-LV Site Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02141672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 17, 2021 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02141672 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →